Currently submitted to: Journal of Medical Internet Research
Date Submitted: Jan 15, 2025
Open Peer Review Period: Jan 15, 2025 - Mar 12, 2025
(currently open for review)
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
An Evidence-Based Digital Prescription Opioid Safety Toolkit for National Dissemination: Co-design and User Testing
ABSTRACT
Background:
Australia has one of the highest rates of opioid prescribing and prescription opioid-related harm in the world. Although effective for acute pain relief, the use of prescription opioids is a leading cause of preventable morbidity and mortality. Major barriers exist for consumers in identifying their own risk factors and accessing naloxone (an opioid overdose antidote) and overdose prevention education.
Objective:
This study aimed to co-design a digital Opioid Safety Toolkit for national dissemination through pharmacies to encourage three consumer opioid safety behaviours: 1) the uptake of naloxone, 2) creating a safety plan, and 3) discussing their use of opioids, including any concerns with their healthcare professional.
Methods:
The digital Toolkit was co-designed and developed using a novel approach to digital health intervention design combining the Theoretical Domains Framework (TDF) and Double-Diamond design process. Co-design involved a series of seven iterative workshops with consumers (4) and professionals (3). Workshops focused on identifying barriers and facilitators to each opioid safety behaviour, exploring design preferences, sense checking and ideation of the user flow. User testing was conducted with the penultimate version of the Toolkit.
Results:
A total of 13 consumers with lived experience of prescription opioid use participated in up to three workshops and 14 professionals including prescribers, pharmacists, pain specialists, researchers and consumer advocates participated in up to three workshops. A further 15 consumers participated in user testing interviews. Analysis of the workshops identified five TDF domains and subsequent sub-themes – Knowledge; Social/professional role and identity; Environment, context and resources; Social support; and Beliefs about capabilities. Factors identified as promoting safety behaviours included increased public awareness of naloxone and its availability, understanding personal risk (TDF domain of Knowledge); healthcare professional’s role in education and consumers’ experience of stigma (Social/professional role and identity); use of conversational aids to scaffold conversations between consumers and healthcare professionals, and material resources and data ownership (Environment, context and resources). User testing elicited feedback pertaining to the information and resources on the website and the overall user interface and experience.
Conclusions:
The Opioid Safety Toolkit was co-designed with consumers and experts to facilitate opioid safety behaviours. The Toolkit includes evidence-based information on the benefits and harms of prescription opioids, tools for risk assessment and screening, opioid use monitoring, conversation aids, and a safety plan. The Toolkit is being disseminated nationally through Australian pharmacies following a randomised controlled trial that demonstrated the Toolkit promotes safety behaviours, is easy to use and acceptable to those with lived experience of prescription opioid use and professionals.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.